Management

There is currently no cure for FOXG1 syndrome, and current interventions are focused on symptom management and supportive therapies where a multidisciplinary approach is essential.

Antiepileptic therapy is often required for seizure control, although seizures can be refractory (don’t respond to medications). Although seizure types may evolve over time, common medications include valproate, topiramate, and others, and sometimes multiple are administered in combination with each other. Clinicians monitor EEG patterns and adjust antiseizure medications as the child grows. Movement disorders (chorea, dystonia) are similarly challenging, and standard interventions (e.g. dopaminergic agents, benzodiazepines, or baclofen for dystonia) have variable benefits. As well, movement disorders must be managed with supportive care and safety measures. Spasticity, if present, may respond to baclofen. Feeding difficulties are addressed with nutritional support such as a feeding gastrostomy tube to ensure adequate intake and prevent aspiration. Early intervention with feeding therapy can help optimize oral skills, but given the high prevalence of swallowing dysfunction, G-tube placement is common. Physical, occupational, and speech therapies are important to maximally support development and prevent contractures.

Innovative research projects are actively exploring disease-specific treatments for FOXG1 syndrome. One promising intervention is gene replacement therapy. A 2024 preclinical study demonstrated that delivering a functional FOXG1 gene via adeno-associated virus serotype 9 (AAV9) can significantly rescue the FOXG1-deficient phenotype in mice. In that study, newborn Foxg1^+/− mice received an intracerebroventricular injection of AAV9 carrying FOXG1, which ameliorated a wide range of neuropathological features. Specifically, it restored corpus callosum structure, normalized hippocampal anatomy (dentate gyrus) and neuronal layering, and corrected hypomyelination by normalizing oligodendrocyte populations. Treated mice showed improved coordination and survival. These results highlight AAV9-based FOXG1 gene therapy as a viable strategy to address the root cause of the syndrome. Notably, benefits were observed even when therapy was given postnatally, suggesting a potential therapeutic window after birth. Another experimental approach is genome editing using the CRISPR/Cas9 system to precisely correct FOXG1 mutations in patient-derived cells. However, gene editing for neurological disorders remains in early development and faces many technical hurdles before clinical use.